The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Long-Acting Injectable (LAI) Antipsychotic Market Research Report 2024
Synopsis
Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
Global Long-Acting Injectable (LAI) Antipsychotic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Long-Acting Injectable (LAI) Antipsychotic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Long-Acting Injectable (LAI) Antipsychotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
Sumitomo Dainippon Pharma
Segment by Type
Aripiprazole
Fluphenazine
Haloperidol
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Long-Acting Injectable (LAI) Antipsychotic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
Global Long-Acting Injectable (LAI) Antipsychotic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Long-Acting Injectable (LAI) Antipsychotic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Long-Acting Injectable (LAI) Antipsychotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
Sumitomo Dainippon Pharma
Segment by Type
Aripiprazole
Fluphenazine
Haloperidol
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Long-Acting Injectable (LAI) Antipsychotic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Aripiprazole
1.2.3 Fluphenazine
1.2.4 Haloperidol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Perspective (2018-2029)
2.2 Long-Acting Injectable (LAI) Antipsychotic Growth Trends by Region
2.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Region (2018-2023)
2.2.3 Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Region (2024-2029)
2.3 Long-Acting Injectable (LAI) Antipsychotic Market Dynamics
2.3.1 Long-Acting Injectable (LAI) Antipsychotic Industry Trends
2.3.2 Long-Acting Injectable (LAI) Antipsychotic Market Drivers
2.3.3 Long-Acting Injectable (LAI) Antipsychotic Market Challenges
2.3.4 Long-Acting Injectable (LAI) Antipsychotic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue
3.1.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue (2018-2023)
3.1.2 Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Players (2018-2023)
3.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Injectable (LAI) Antipsychotic Revenue
3.4 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio
3.4.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2022
3.5 Long-Acting Injectable (LAI) Antipsychotic Key Players Head office and Area Served
3.6 Key Players Long-Acting Injectable (LAI) Antipsychotic Product Solution and Service
3.7 Date of Enter into Long-Acting Injectable (LAI) Antipsychotic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Injectable (LAI) Antipsychotic Breakdown Data by Type
4.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Type (2018-2023)
4.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Type (2024-2029)
5 Long-Acting Injectable (LAI) Antipsychotic Breakdown Data by Application
5.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Application (2018-2023)
5.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
6.2 North America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
6.4 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
7.2 Europe Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
7.4 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
8.2 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023)
8.4 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
9.2 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
9.4 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)
10.2 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
10.4 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Detail
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Introduction
11.1.4 Alkermes Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.1.5 Alkermes Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Detail
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Introduction
11.2.4 Eli Lilly and Company Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.2.5 Eli Lilly and Company Recent Development
11.3 Janssen Global Services, LLC
11.3.1 Janssen Global Services, LLC Company Detail
11.3.2 Janssen Global Services, LLC Business Overview
11.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Introduction
11.3.4 Janssen Global Services, LLC Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.3.5 Janssen Global Services, LLC Recent Development
11.4 Abilify Maintena
11.4.1 Abilify Maintena Company Detail
11.4.2 Abilify Maintena Business Overview
11.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Introduction
11.4.4 Abilify Maintena Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.4.5 Abilify Maintena Recent Development
11.5 Haldol
11.5.1 Haldol Company Detail
11.5.2 Haldol Business Overview
11.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Introduction
11.5.4 Haldol Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.5.5 Haldol Recent Development
11.6 Otsuka Pharmaceutical
11.6.1 Otsuka Pharmaceutical Company Detail
11.6.2 Otsuka Pharmaceutical Business Overview
11.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Introduction
11.6.4 Otsuka Pharmaceutical Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.6.5 Otsuka Pharmaceutical Recent Development
11.7 Aristada
11.7.1 Aristada Company Detail
11.7.2 Aristada Business Overview
11.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Introduction
11.7.4 Aristada Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.7.5 Aristada Recent Development
11.8 Prolixin
11.8.1 Prolixin Company Detail
11.8.2 Prolixin Business Overview
11.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Introduction
11.8.4 Prolixin Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.8.5 Prolixin Recent Development
11.9 Sumitomo Dainippon Pharma
11.9.1 Sumitomo Dainippon Pharma Company Detail
11.9.2 Sumitomo Dainippon Pharma Business Overview
11.9.3 Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Introduction
11.9.4 Sumitomo Dainippon Pharma Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)
11.9.5 Sumitomo Dainippon Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
